Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;165(1):112-6.
doi: 10.1111/bjh.12715. Epub 2014 Jan 6.

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

Yasuhiro Oki  1 , Hubert Chuang, Beth Chasen, Aaron Jessop, Tinsu Pan, Michelle Fanale, Bouthaina Dabaja, Nathan Fowler, Jorge Romaguera, Luis Fayad, Fredrick Hagemeister, Maria Alma Rodriguez, Sattva Neelapu, Felipe Samaniego, Larry Kwak, Anas Younes
Affiliations

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

Yasuhiro Oki et al. Br J Haematol. 2014 Apr.

Abstract

The prognostic value of interim positron emission tomography (PET) was evaluated after 2 cycles of doxorubicin, bleomycin, vinblastin and dacarbazine in classical Hodgkin lymphoma patients (n = 229), based on Deauville criteria. In early stage non-bulky disease, bulky stage II disease, advanced stage low International Prognostic Score (IPS ≤2) and advanced stage (IPS ≥3), 3-year progression-free survival rates in PET2-negative vs. PET2-positive groups were 95·9% vs. 76·9% (P < 0·0018), 83·3% vs. 20·0% (P = 0·017), 77·0% vs. 30·0% (P < 0·001) and 71·0% vs. 44·4%(P = 0·155), respectively. The outcome after positive PET2 was better than previously reported. The results from non-randomized studies of PET2-guided therapy would be valuable with careful interpretation.

Keywords: Hodgkin lymphoma; positron emission tomography; prognostic.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Hazard ratio of PET2 positivity in different disease subgroups. PET2, positron emission tomography scan after 2 cycles of chemotherapy; IPS, international Prognostic score.
Fig 2
Fig 2
Kaplan–Meier Curves of A. Progression-free survival in patients with early stage favourable disease by PET2 (Deauville criteria; Meignan et al, 2009), B. Progression-free survival in patients with early stage unfavourable disease by PET2 (Deauville criteria), C. Progression-free survival in patients with early stage non-bulky disease by PET2 (Deauville criteria), D. Progression-free survival in patients with stage II bulky disease by PET2 (Deauville criteria), E. Progression-free survival in patients with advanced stage with IPS score ≤2 by PET2 (Deauville criteria), F. Progression-free survival in patients with advanced stage with IPS score ≥3 by PET2 (Deauville criteria), G. Progression-free survival in patients with early stage non-bulky disease by PET2 (Juweid criteria; Juweid et al, 2007), H. Progression-free survival in patients with stage II bulky disease by PET2 (Juweid criteria). PFS, progression-free survival; PET2, positron emission tomography scan after 2 cycles of chemotherapy; IPS, International Prognostic score.
See this image and copyright information in PMC

References

    1. Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, Meignan M, Malkowski B, Hofman MS, Barrington SF. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. Journal of Nuclear Medicine. 2013;54:683–690. - PubMed
    1. Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, Trindade E, Soares J, Jr, Buccheri V, Meneghetti JC. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. Journal of Nuclear Medicine. 2010;51:1337–1343. - PubMed
    1. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of Clinical Oncology. 2007;25:3746–3752. - PubMed
    1. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D'Amore F, Boesen AM, Berthelsen AK, Specht L. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–59. - PubMed
    1. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD, Imaging Subcommittee of International Harmonization Project in, L. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. Journal of Clinical Oncology. 2007;25:571–578. - PubMed